8UAK

Crystal structure of the catalytic domain of human PKC alpha (D463N, V568I, S657E) in complex with Darovasertib (NVP-LXS196) at 2.82-A resolution

Summary for 8UAK

• Entry DOI: 10.2210/pdb8uak/pdb
• Related: 8u37
• Descriptor: Protein kinase C alpha type, (6M)-3-amino-N-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide (3 entities in total)
• Functional Keywords: inhibitor, complex, darovasertib, nvp-lxs196, nvp-cjl037, 8u37, transferase-inhibitor complex, transferase/inhibitor
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 1
• Total formula weight: 41153.88

Authors

Romanowski, M.J.,Lam, J.,Visser, M. (deposition date: 2023-09-21, release date: 2024-01-24, Last modification date: 2024-01-31)

• Primary citation: Visser, M.,Papillon, J.P.N.,Luzzio, M.,LaMarche, M.J.,Fan, J.,Michael, W.,Wang, D.,Zhang, A.,Straub, C.,Mathieu, S.,Kato, M.,Palermo, M.,Chen, C.,Ramsey, T.,Joud, C.,Barrett, R.,Vattay, A.,Guo, R.,Bric, A.,Chung, F.,Liang, G.,Romanowski, M.J.,Lam, J.,Thohan, S.,Atassi, F.,Wylie, A.,Cooke, V.G.; Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma.; J.Med.Chem., 67:1447-1459, 2024; PubMed: 38198520; DOI: 10.1021/acs.jmedchem.3c02002

Experimental method

X-RAY DIFFRACTION (2.82 Å)